Syndax Pharmaceuticals, Inc. (SNDX) financial statements (2021 and earlier)

Company profile

Business Address 35 GATEHOUSE DRIVE
WALTHAM, MA 02451
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments2936081130105
Cash and cash equivalents11525343524
Short-term investments17835479581
Restricted cash and investments  000
Receivables00000
Prepaid expense11111
Deposits current assets51112
Other undisclosed current assets00110
Total current assets:2996283133109
Noncurrent Assets
Operating lease, right-of-use asset01
Property, plant and equipment00000
Long-term investments and receivables   3 
Long-term investments   3 
Other noncurrent assets10000
Total noncurrent assets:21141
TOTAL ASSETS:3016484137109
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities810555
Accounts payable46122
Accrued liabilities11101
Employee-related liabilities33322
Deferred revenue22
Debt20   
Deferred revenue and credits21
Contract with customer, liability2
Other undisclosed current liabilities771094
Total current liabilities:1918161610
Noncurrent Liabilities
Long-term debt and lease obligation180   
Long-term debt, excluding current maturities18    
Operating lease, liability00
Liabilities, other than long-term debt1213151715
Deferred revenue and credits1714
Deferred revenue1213
Contract with customer, liability15
Other liabilities00000
Total noncurrent liabilities:3014151715
Total liabilities:4832313325
Stockholders' equity
Stockholders' equity attributable to parent252325310484
Common stock00000
Additional paid in capital821527492471389
Accumulated other comprehensive income (loss)(0) (0)(0)0
Accumulated deficit(569)(495)(439)(366)(305)
Total stockholders' equity:252325310484
TOTAL LIABILITIES AND EQUITY:3016484137109

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenue, net21
Gross profit:22221
Operating expenses(73)(59)(77)(64)(45)
Operating loss:(71)(58)(76)(62)(44)
Nonoperating income (expense)(2)121(1)
Investment income, nonoperating1    
Other nonoperating income (expense)(0)(0)(0)(0)0
Interest and debt expense(2)    
Loss before gain (loss) on sale of properties:(76)(56)(74)(61)(44)
Other undisclosed net income2    
Net loss attributable to parent:(73)(56)(74)(61)(44)
Preferred stock dividends and other adjustments    (3)
Other undisclosed net loss available to common stockholders, basic(4)    
Net loss available to common stockholders, diluted:(77)(56)(74)(61)(47)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(73)(56)(74)(61)(44)
Comprehensive loss:(73)(56)(74)(61)(44)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)00(0)0
Comprehensive loss, net of tax, attributable to parent:(73)(56)(74)(61)(44)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: